SBIR/STTR Research Award

Development of A Novel Magnetic Exosomal Assay for Diagnosis of Diseases with Impaired Vascular Integrity

Award identifier dd768478a94b8633c4f35e9388c1a4e045190483e6c084256be6d2763dad7513Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$200,000

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Microsensor Labs, LLC
Proposal award date
2016-07-01
Contract end date
2017-06-30
UEI
ZJR3H843V6U4
Solicitation number
PA16-414
Topic code
NHLBI

Research abstract

DESCRIPTION provided by applicant This Small Business Innovation Research Phase project aims to develop and characterize a novel Magnetic Exosomal Assay to isolate and detect single intact exosome concentrations in human serum This proposed research will also evaluate the diagnostic potential of the Magnetic Exosomal Assay for diseases with impaired vascular integrity Vascular integrity or the maintenance of blood vessel continuity is a fundamental process maintained through endothelial cell cell junctions Defects in endothelial barrier function are an initiating factor in several disease processes including atherosclerosis ischemia reperfusion tumor angiogenesis cancer metastasis diabetes sepsis and acute lung injury An initial event in impaired vascular integrity is a dramatic increase in a novel type of extracellular vesicle EV from endothelial cells EC called exosomes Therefore the development of a highly sensitive reproducible and easy to implement assay to detect exosome concentrations in complex clinical samples can have potential diagnostic and therapeutic benefit In this research proposal we will develop and characterize a novel Magnetic Exosomal Assay kit and reader for fast isolation and detection of single intact exosome concentrations in human serum In addition we will assess the optimized Magnetic Exosomal Assay on Community Acquired Pneumonia patient serum The ultimate goal of this research is to develop a highly sensitive reproducible and easy to implement exosomal assay as a diagnostic tool for patients with various types of impaired vascular integrity related diseases PUBLIC HEALTH RELEVANCE This Small Business Innovation Research Phase project aims to develop and characterize a novel Magnetic Exosomal Assay to isolate and detect single intact exosome concentrations in human serum Successful completion of the project will advance diagnosis and prognosis for patients with various types of impaired vascular integrity related diseases which often disproportionally affect women the elderly and disadvantaged and or underrepresented races and or ethnicities

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2016–2025). Reported award amounts total $4,956,555. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.